Citigroup Downgrades Agilon Health to Sell, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Daniel Grosslight has downgraded Agilon Health from Neutral to Sell and reduced the price target from $7 to $2.5.
October 29, 2024 | 9:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has downgraded Agilon Health to Sell and significantly lowered its price target to $2.5, indicating a negative outlook.
The downgrade from Neutral to Sell by a major financial institution like Citigroup, along with a drastic reduction in the price target, suggests a negative short-term outlook for Agilon Health. This is likely to lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100